Serologic Testing for Celiac Disease in Graves’ Hyperthyroidism: Should We Act Early?
- 10 August 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 47 (1), 26-31
- https://doi.org/10.1080/07435800.2021.1959607
Abstract
Background: The general practice is to screen patients with autoimmune thyroid disease for celiac disease (CD); however, optimal timing for CD screening for patients with Graves’Disease (GD) has not been identified yet. The aim of the study was to show whether positive celiac antibodies persist after euthyroidism is achieved. Materials and Methods: Serum samples were collected from 35 patients with GD (23 female and 12 male) who applied to the endocrine outpatient clinic. Patients and healthy controls were screened for CD with IgG and IgA antigliadin antibodies (IgG – AGA and IgA – AGA), IgA endomysial antibody (IgA-EMA) and IgA tissue transglutaminase antibody (IgA anti-tTG). These antibodies were reevaluated when patients were euthyroid under antithyroid therapy. Small intestine biopsy was offered to the patients who remained antibody positive after being euthyroid. Results: Screening 35 patients with GD revealed positive results for IgA-AGA (n = 6/35, 17%), IgG-AGA (n = 9/35, 26%), IgA-EmA (n = 2/35, 6%) and IgA-tTG (n = 2/35, 6%). No patient had multiple antibodies positive. Selective IgA deficiency was not detected in patients and controls. When patients were euthyroid, baseline positive IgA-AGA, IgG-AGA, and IgA-EmA became negative, while positive anti-tTG persisted in two patients. Endoscopic duodenal biopsy showed a normal villi/crypts ratio in these patients. None of the controls had positive antibodies. Conclusion: Due to possibility of false seropositivity of celiac antibodies in patients with Graves’ thyrotoxicosis, one should defer testing for CD until euthyroidism has been achieved.Keywords
Funding Information
- The study was funded by Istanbul University Scientific Study Project Fund
This publication has 29 references indexed in Scilit:
- Quality not quantity for transglutaminase antibody 2: the performance of an endomysial and tissue transglutaminase test in screening coeliac disease remains stable over timeClinical and Experimental Immunology, 2012
- Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodiesClinical Endocrinology, 2005
- Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac diseaseEuropean Journal of Gastroenterology & Hepatology, 2005
- Anti-human versus anti-guinea pig tissue transglutaminase antibodies as the first-level serological screening test for coeliac disease in the general populationDigestive and Liver Disease, 2004
- A comparison of 13 guinea pig and human anti-tissue transglutaminase antibody ELISA kitsJournal of Clinical Pathology, 2002
- Histopathology of celiac diseaseBiomedicine & Pharmacotherapy, 2000
- Fas Ligand Expression in Thyroid Follicular Cells from Patients with Thionamide-Treated Graves' DiseaseThyroid®, 2000
- Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac diseaseGastroenterology, 1999
- Evidence of Transient IgA Anti-Endomysial Antibody Positivity in a Patient with Graves’ DiseaseDigestion, 1999
- Induction of Circulating Activated Suppressor-like T Cells by Methimazole Therapy for Graves' DiseaseThe New England Journal of Medicine, 1987